Difficulty: Medium
Average Score: 83%
Practice
Montelukast:
Correct answer
A
Rationale
Montelukast is a leukotriene receptor antagonist used in the treatment of asthma and allergic rhinitis. The correct answer, A) Is a competitive antagonist at the Cys LTÔéü receptor, is the right choice because Montelukast specifically targets and blocks the action of cysteinyl leukotrienes at the Cys LTÔéü receptor, thereby reducing inflammation and bronchoconstriction in the airways.
Option B, Can be given orally, is a common route of administration for Montelukast, but it does not address its mechanism of action. Option C, Is usually taken once daily at bedtime, is partially true as Montelukast is often prescribed once daily due to its long half-life, but this does not explain its pharmacological action. Option D, May be associated with Churg-Strauss syndrome, is incorrect as Montelukast is not known to be associated with this syndrome.
In an educational context, understanding the mechanism of action of drugs is crucial for healthcare professionals to make informed decisions about their use in clinical practice. Knowing that Montelukast is a competitive antagonist at the Cys LTÔéü receptor helps in understanding how it works and its potential therapeutic effects in respiratory conditions. It also highlights the importance of selecting the most appropriate drug based on its mechanism of action for optimal patient outcomes.
Option B, Can be given orally, is a common route of administration for Montelukast, but it does not address its mechanism of action. Option C, Is usually taken once daily at bedtime, is partially true as Montelukast is often prescribed once daily due to its long half-life, but this does not explain its pharmacological action. Option D, May be associated with Churg-Strauss syndrome, is incorrect as Montelukast is not known to be associated with this syndrome.
In an educational context, understanding the mechanism of action of drugs is crucial for healthcare professionals to make informed decisions about their use in clinical practice. Knowing that Montelukast is a competitive antagonist at the Cys LTÔéü receptor helps in understanding how it works and its potential therapeutic effects in respiratory conditions. It also highlights the importance of selecting the most appropriate drug based on its mechanism of action for optimal patient outcomes.